Apolipoprotein E Explained

Apolipoprotein E (Apo-E) is a protein involved in the metabolism of fats in the body of mammals. A subtype is implicated in Alzheimer's disease and cardiovascular diseases.[1] It is encoded in humans by the gene APOE.

Apo-E belongs to a family of fat-binding proteins called apolipoproteins. In the circulation, it is present as part of several classes of lipoprotein particles, including chylomicron remnants, VLDL, IDL, and some HDL.[2] Apo-E interacts significantly with the low-density lipoprotein receptor (LDLR), which is essential for the normal processing (catabolism) of triglyceride-rich lipoproteins.[3] In peripheral tissues, Apo-E is primarily produced by the liver and macrophages, and mediates cholesterol metabolism. In the central nervous system, Apo-E is mainly produced by astrocytes and transports cholesterol to neurons[4] via Apo-E receptors, which are members of the low density lipoprotein receptor gene family. Apo-E is the principal cholesterol carrier in the brain.[5] APOE qualifies as a checkpoint inhibitor of the classical complement pathway by complex formation with activated C1q.[6]

Evolution

Apolipoproteins are not unique to mammals. Many terrestrial and marine vertebrates have versions of them.[7] It is believed that APOE arose via gene duplications of APOC1 before the fish–tetrapod split ca. 400 million years ago. Proteins similar in function have been found in choanoflagellates, suggesting that they are a very old class of proteins predating the dawn of all living animals.[8]

The three major human alleles (E4, E3, E2) arose after the primate–human split around 7.5 million years ago. These alleles are the by-product of non-synonymous mutations which led to changes in functionality. The first allele to emerge was E4. After the primate–human split, there were four amino acid changes in the human lineage, three of which had no effect on protein function (V174L, A18T, A135V). The fourth substitution (T61R) traded a threonine for an arginine altering the protein's functionality. This substitution occurred somewhere in the 6 million year gap between the primate–human split and the Denisovan–human split, since exactly the same substitutions were found in Denisovan APOE.[9]

About 220,000 years ago, a cysteine to arginine substitution took place at amino acid 112 (Cys112Arg) of the APOE4 gene, and this resulted in the E3 allele. Finally, 80,000 years ago, another arginine to cysteine substitution at amino acid 158 (Arg158Cys) of the APOE3 gene created the E2 allele.[10] [8]

Structure

Gene

The gene, APOE, is mapped to chromosome 19 in a cluster with the apolipoprotein C1 (APOC1) gene and the apolipoprotein C2 (APOC2) gene. The APOE gene consists of four exons and three introns, totaling 3597 base pairs. APOE is transcriptionally activated by the liver X receptor (an important regulator of cholesterol, fatty acid, and glucose homeostasis) and peroxisome proliferator-activated receptor γ, nuclear receptors that form heterodimers with retinoid X receptors.[11] In melanocytic cells APOE gene expression may be regulated by MITF.[12]

Protein

Apoe-E is 299 amino acids long and contains multiple amphipathic α-helices. According to crystallography studies, a hinge region connects the N- and C-terminal regions of the protein. The N-terminal region (residues 1–167) forms an anti-parallel four-helix bundle such that the non-polar sides face inside the protein. Meanwhile, the C-terminal domain (residues 206–299) contains three α-helices which form a large exposed hydrophobic surface and interact with those in the N-terminal helix bundle domain through hydrogen bonds and salt-bridges. The C-terminal region also contains a low density lipoprotein receptor (LDLR)-binding site.[13]

Polymorphisms

Rsid:429358
Gene:ApoE
Chromosome:19

APOE is polymorphic,[14] [15] with three major alleles (epsilon 2, epsilon 3, and epsilon 4): APOE-ε2 (cys112, cys158), APOE-ε3 (cys112, arg158), and APOE-ε4 (arg112, arg158).[1] [16] Although these allelic forms differ from each other by only one or two amino acids at positions 112 and 158,[17] these differences alter APOE structure and function.

There are several low-frequency polymorphisms of APOE. APOE5 comes in two subtypes E5f and E5s, based on migration rates. APOE5 E5f and APOE7 combined were found in 2.8% of Japanese males.[18] APOE7 is a mutation of APOE3 with two lysine residues replacing glutamic acid residues at positions 244 and 245.[19]

PolymorphismWorldwide allele frequencyDisease relevance
ε2 (rs7412-T, rs429358-T)8.4%[20] This variant of the apoprotein binds poorly to cell surface receptors while E3 and E4 bind well.[21] E2 is associated with both increased and decreased risk for atherosclerosis. Individuals with an E2/E2 combination may clear dietary fat slowly and be at greater risk for early vascular disease and the genetic disorder type III hyperlipoproteinemia—94.4% of people with such disease are E2/E2 but only ~2% of E2/E2 develop it, so other environmental and genetic factors are likely to be involved (such as cholesterol in the diet and age).[22] [23] [24] E2 has also been implicated in Parkinson's disease,[25] but this finding was not replicated in a larger population association study.[26]
ε3 (rs7412-C, rs429358-T)77.9%This variant is considered the "neutral" APOE genotype.
ε4 (rs7412-C, rs429358-C)13.7%E4 has been implicated in atherosclerosis,[27] [28] Alzheimer's disease,[29] [30] impaired cognitive function,[31] [32] reduced hippocampal volume,[33] HIV,[34] faster disease progression in multiple sclerosis,[35] [36] unfavorable outcome after traumatic brain injury,[37] ischemic cerebrovascular disease,[38] sleep apnea,[39] [40] both the extension and shortening of telomeres,[41] [42] [43] [44] reduced neurite outgrowth,[45] and COVID-19.[46] However, E4 has also been associated with enhanced vitamin D and calcium status,[47] higher fecundity,[48] protection against early childhood infection and malnutrition,[49] and decreased fetal, perinatal, and infant mortality.[50]
Much remains to be learned about the APOE isoforms, including the interaction of other protective genes.[51] Indeed, the apolipoprotein ε4 isoform is more protective against cognitive decline than other isoforms in some cases,[51] so caution is advised before making determinant statements about the influence of APOE polymorphisms on cognition, development of Alzheimer's disease, cardiovascular disease, telomere shortening, etc. Many of the studies cited that purport these adverse outcomes are from single studies that have not been replicated and the research is based on unchecked assumptions about this isoform. As of 2007, there was no evidence that APOE polymorphisms influence cognition in younger age groups (other than possible increased episodic memory ability and neural efficiency in younger APOE4 age groups), nor that the APOE4 isoform places individuals at increased risk for any infectious disease.[52]

However, the association between the APOE4 allele and Alzheimer's disease has been shown to be weaker in minority groups differently compared to their Caucasian counterparts. Hispanics/Latinos and African Americans who were homozygous for the APOE4 allele had 2.2 and 5.7 times the odds, respectively of developing Alzheimer's disease.[53] The APOE4 allele has an even stronger effect in East Asian populations, with Japanese populations have 33 times the odds compared to other populations.[54] Caucasians who were homozygous for the allele had 12.5 times the odds.

Function

As a component of the lipoprotein lipid transport system, APOE facilitates the transport of lipids, fat-soluble vitamins, and cholesterol via the blood. It interacts with the LDL receptor to facilitate endocytosis of VLDL remnants. It is synthesized principally in the liver, but has also been found in other tissues such as the brain, kidneys, and spleen.[55] APOE synthesized in the liver associates with HDL which can then distribute it to newly formed VLDL or chylomicron particles to facilitate their eventual uptake by the liver.

In the nervous system, non-neuronal cell types, most notably astroglia and microglia, are the primary producers of APOE, while neurons preferentially express the receptors for APOE.[56] There are seven currently identified mammalian receptors for APOE which belong to the evolutionarily conserved LDLR family.[57]

APOE was initially recognized for its importance in lipoprotein metabolism and cardiovascular disease. Defects in APOE result in familial dysbetalipoproteinemia aka type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron, VLDL and LDL.[58] [3] More recently, it has been studied for its role in several biological processes not directly related to lipoprotein transport, including Alzheimer's disease (AD), immunoregulation, and cognition.[1] Though the exact mechanisms remain to be elucidated, isoform 4 of APOE, encoded by an APOE allele, has been associated with increased calcium ion levels and apoptosis following mechanical injury.[59]

In the field of immune regulation, a growing number of studies point to APOE's interaction with many immunological processes, including suppressing T cell proliferation, macrophage functioning regulation, lipid antigen presentation facilitation (by CD1)[60] to natural killer T cell as well as modulation of inflammation and oxidation.[61] APOE is produced by macrophages and APOE secretion has been shown to be restricted to classical monocytes in PBMC, and the secretion of APOE by monocytes is down regulated by inflammatory cytokines and upregulated by TGF-beta.[62]

Clinical significance

Alzheimer's disease

As of 2012, the E4 variant was the largest known genetic risk factor for late-onset sporadic Alzheimer's disease (AD) in a variety of ethnic groups.[63] However, the E4 variant does not correlate with risk in every population. Nigerian people have the highest observed frequency of the APOE4 allele in world populations,[64] but AD is rare among them.[65] This may be due to their low cholesterol levels.[66] [67] Caucasian and Japanese carriers of two E4 alleles have between 10 and 30 times the risk of developing AD by 75 years of age, as compared to those not carrying any E4 alleles. This may be caused by an interaction with amyloid.[68] Alzheimer's disease is characterized by build-ups of aggregates of the peptide beta-amyloid. Apolipoprotein E enhances proteolytic break-down of this peptide, both within and between cells. The isoform APOE-ε4 is not as effective as the others at promoting these reactions, resulting in increased vulnerability to AD in individuals with that gene variation.[69]

Recently, the amyloid hypothesis of Alzheimer's disease has been questioned, and an article in Science claimed that "Just as removing smoke does not extinguish a fire, reducing amyloid plaques may not affect the course of Alzheimer's disease."[70] The role that the E4 variant carries can still be fully explained even in the absence of a valid amyloid hypothesis given the fact that reelin signaling emerges to be one of the key processes involved in Alzheimer's disease[71] and the E4 variant is shown to interact with ApoER2, one of the neuronal reelin receptors, thereby obstructing reelin signaling.[71]

Although 40–65% of AD patients have at least one copy of the ε4 allele, APOE4 is not a determinant of the disease. At least one-third of patients with AD are APOE4 negative and some APOE4 homozygotes never develop the disease. Yet those with two ε4 alleles have up to 20 times the risk of developing AD.[72] There is also evidence that the APOE2 allele may serve a protective role in AD.[73] Thus, the genotype most at risk for Alzheimer's disease and at an earlier age is APOE4,4. Using genotype APOE3,3 as a benchmark (with the persons who have this genotype regarded as having a risk level of 1.0) and for white populations only, individuals with genotype APOE4,4 have an odds ratio of 14.9 of developing Alzheimer's disease. Individuals with the APOE3,4 genotype face an odds ratio of 3.2, and people with a copy of the 2 allele and the 4 allele (APOE2,4), have an odds ratio of 2.6. Persons with one copy each of the 2 allele and the 3 allele (APOE2,3) have an odds ratio of 0.6. Persons with two copies of the 2 allele (APOE2,2) also have an odds ratio of 0.6.[74]

Estimated worldwide human allele frequencies of APOE in Caucasian population
Alleleε2ε3ε4
General frequency8.4%77.9%13.7%
AD frequency3.9%59.4%36.7%
While ApoE4 has been found to greatly increase the odds that an individual will develop Alzheimer's, a 2002 study concluded, that in persons with any combination of APOE alleles, high serum total cholesterol and high blood pressure in mid-life are independent risk factors which together can nearly triple the risk that the individual will later develop AD. Projecting from their data, some researchers have suggested that lowering serum cholesterol levels may reduce a person's risk for Alzheimer's disease, even if they have two ApoE4 alleles, thus reducing the risk from nine or ten times the odds of getting AD down to just two times the odds.

Women are more likely to develop AD than men across most ages and APOE genotypes. Premorbid women with the ε4 allele have significantly more neurological dysfunction than men.[75]

APOE-ε4 increases the risk not only for AD but also for dementia in pure alpha-synucleinopathies.[76] The influence of APOE-ε4 on hippocampal atrophy was suggested to be more predominant early in the course of AD at milder stages prior to more widespread neurodegeneration.[77]

Atherosclerosis

Knockout mice that lack the apolipoprotein-E gene (APOE−/−) develop extreme hypercholesterolemia when fed a high-fat diet.[78]

Malaria

APOE−/− knockout mice show marked attenuation of cerebral malaria and increased survival, as well as decreased sequestration of parasites and T cells within the brain, likely due to protection of the blood–brain barrier.[79] Human studies have shown that the APOE2 polymorphism correlates with earlier infection, and APOE3/4 polymorphisms increase likelihood of severe malaria.[80]

Lyme disease

Borrelia burgdorferi, the causative agent of Lyme disease, is a host-adapted pathogen that acquires environmental cholesterol to form glycolipids for use in cell membrane maintenance. In one experiment in 2015, mice engineered with apoE deficiency were infected with Borrelia spirochetes. The knockout mice suffered from an increased spirochete burden in joints, as well as inflamed ankles, when compared with wild-type mice. This study suggests that apoE deficiency (and potentially other hyperlipidemias) may be a risk factor in the pathogenicity of Lyme disease.

Interactions

Interactive pathway map

Further reading

External links

Notes and References

  1. Book: Stolerman IP . Encyclopedia of Psychopharmacology . 2010 . Springer . Berlin . 978-3540686989 . Online .
  2. Mahley RW, Weisgraber KH, Huang Y . Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS . Journal of Lipid Research . 50 . Suppl . S183–S188 . April 2009 . 19106071 . 2674716 . 10.1194/jlr.R800069-JLR200 . free .
  3. Web site: Entrez Gene: APOE apolipoprotein E.
  4. Wang H, Kulas JA, Wang C, Holtzman DM, Ferris HA, Hansen SB . Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol . Proceedings of the National Academy of Sciences of the United States of America . 118 . 33 . 2020.06.18.159632 . August 2021 . 34385305 . 8379952 . 10.1073/pnas.2102191118 . 220044671 . free . 2021PNAS..11802191W . 10.1101/2020.06.18.159632 .
  5. Puglielli L, Tanzi RE, Kovacs DM . Alzheimer's disease: the cholesterol connection . Nature Neuroscience . 6 . 4 . 345–351 . April 2003 . 12658281 . 10.1038/nn0403-345 . 5407666 .
  6. Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, Nietzsche S, Westermann M, Peng L, Hu D, Bontha SV, Srikakulapu P, Beer M, Megens RT, Steffens S, Hildner M, Halder LD, Eckstein HH, Pelisek J, Herms J, Roeber S, Arzberger T, Borodovsky A, Habenicht L, Binder CJ, Weber C, Zipfel PF, Skerka C, Habenicht AJ . ApoE attenuates unresolvable inflammation by complex formation with activated C1q . Nature Medicine . 25 . 3 . 496–506 . March 2019 . 30692699 . 6420126 . 10.1038/s41591-018-0336-8 .
  7. Babin PJ, Thisse C, Durliat M, Andre M, Akimenko MA, Thisse B . Both apolipoprotein E and A-I genes are present in a nonmammalian vertebrate and are highly expressed during embryonic development . Proceedings of the National Academy of Sciences of the United States of America . 94 . 16 . 8622–8627 . August 1997 . 9238027 . 23048 . 10.1073/pnas.94.16.8622 . free . 1997PNAS...94.8622B .
  8. Huebbe P, Rimbach G . Evolution of human apolipoprotein E (APOE) isoforms: Gene structure, protein function and interaction with dietary factors . Ageing Research Reviews . 37 . 146–161 . August 2017 . 28647612 . 10.1016/j.arr.2017.06.002 . 3758905 .
  9. McIntosh AM, Bennett C, Dickson D, Anestis SF, Watts DP, Webster TH, Fontenot MB, Bradley BJ . The apolipoprotein E (APOE) gene appears functionally monomorphic in chimpanzees (Pan troglodytes) . PLOS ONE . 7 . 10 . e47760 . 2012 . 23112842 . 3480407 . 10.1371/journal.pone.0047760 . free . 2012PLoSO...747760M .
  10. Finch CE, Stanford CB . Meat-adaptive genes and the evolution of slower aging in humans . The Quarterly Review of Biology . 79 . 1 . 3–50 . March 2004 . 15101252 . 10.1086/381662 . 14225962 .
  11. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P . A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis . Molecular Cell . 7 . 1 . 161–171 . January 2001 . 11172721 . 10.1016/S1097-2765(01)00164-2 . free .
  12. Hoek KS, Schlegel NC, Eichhoff OM, Widmer DS, Praetorius C, Einarsson SO, Valgeirsdottir S, Bergsteinsdottir K, Schepsky A, Dummer R, Steingrimsson E . Novel MITF targets identified using a two-step DNA microarray strategy . Pigment Cell & Melanoma Research . 21 . 6 . 665–676 . December 2008 . 19067971 . 10.1111/j.1755-148X.2008.00505.x . 24698373 . free .
  13. Phillips MC . Apolipoprotein E isoforms and lipoprotein metabolism . IUBMB Life . 66 . 9 . 616–623 . September 2014 . 25328986 . 10.1002/iub.1314 . 6159310 .
  14. Singh PP, Singh M, Mastana SS . APOE distribution in world populations with new data from India and the UK . Annals of Human Biology . 33 . 3 . 279–308 . 2006 . 17092867 . 10.1080/03014460600594513 . 34696595 .
  15. Eisenberg DT, Kuzawa CW, Hayes MG . Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history . American Journal of Physical Anthropology . 143 . 1 . 100–111 . September 2010 . 20734437 . 10.1002/ajpa.21298 .
  16. Ghebranious N, Ivacic L, Mallum J, Dokken C . Detection of ApoE E2, E3 and E4 alleles using MALDI-TOF mass spectrometry and the homogeneous mass-extend technology . Nucleic Acids Research . 33 . 17 . e149 . October 2005 . 16204452 . 1243648 . 10.1093/nar/gni155 .
  17. Zuo L, van Dyck CH, Luo X, Kranzler HR, Yang BZ, Gelernter J . Variation at APOE and STH loci and Alzheimer's disease . Behavioral and Brain Functions . 2 . 1 . 13 . April 2006 . 16603077 . 1526745 . 10.1186/1744-9081-2-13 . Christopher H. van Dyck . free .
  18. Yamanouchi Y, Arinami T, Tsuchiya S, Miyazaki R, Takaki H, Takano T, Hamaguchi H . Apolipoprotein E5 and E7 in apparently healthy Japanese males: frequencies and relation to plasma lipid levels . The Japanese Journal of Human Genetics . 39 . 3 . 315–324 . September 1994 . 7841442 . 10.1007/BF01874050 . 20361600 . free .
  19. Dong J, Balestra ME, Newhouse YM, Weisgraber KH . Human apolipoprotein E7:lysine mutations in the carboxy-terminal domain are directly responsible for preferential binding to very low density lipoproteins . Journal of Lipid Research . 41 . 11 . 1783–1789 . November 2000 . 11060347 . 10.1016/S0022-2275(20)31971-4 . free .
  20. Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G . Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy . Nature Reviews. Neurology . 9 . 2 . 106–118 . February 2013 . 23296339 . 3726719 . 10.1038/nrneurol.2012.263 .
  21. Weisgraber KH, Innerarity TL, Mahley RW . Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site . The Journal of Biological Chemistry . 257 . 5 . 2518–2521 . March 1982 . 6277903 . 10.1016/S0021-9258(18)34954-8 . free .
  22. Breslow JL, Zannis VI, SanGiacomo TR, Third JL, Tracy T, Glueck CJ . Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2 . Journal of Lipid Research . 23 . 8 . 1224–1235 . November 1982 . 7175379 . 10.1016/S0022-2275(20)38060-3 . free .
  23. Feussner G, Feussner V, Hoffmann MM, Lohrmann J, Wieland H, März W . Molecular basis of type III hyperlipoproteinemia in Germany . Human Mutation . 11 . 6 . 417–423 . 1998 . 9603433 . 10.1002/(SICI)1098-1004(1998)11:6<417::AID-HUMU1>3.0.CO;2-5 . 39103399 . free .
  24. Civeira F, Pocoví M, Cenarro A, Casao E, Vilella E, Joven J, González J, Garcia-Otín AL, Ordovás JM . Apo E variants in patients with type III hyperlipoproteinemia . Atherosclerosis . 127 . 2 . 273–282 . December 1996 . 9125318 . 10.1016/S0021-9150(96)05969-2 .
  25. Huang X, Chen PC, Poole C . APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease . Neurology . 62 . 12 . 2198–2202 . June 2004 . 15210882 . 10.1212/01.wnl.0000130159.28215.6a . 10445412 .
  26. Federoff M, Jimenez-Rolando B, Nalls MA, Singleton AB . A large study reveals no association between APOE and Parkinson's disease . Neurobiology of Disease . 46 . 2 . 389–392 . May 2012 . 22349451 . 3323723 . 10.1016/j.nbd.2012.02.002 .
  27. Phillips MC . Apolipoprotein E isoforms and lipoprotein metabolism . IUBMB Life . 66 . 9 . 616–623 . September 2014 . 25328986 . 10.1002/iub.1314 . 6159310 .
  28. Mahley RW, Rall SC . Apolipoprotein E: far more than a lipid transport protein . Annual Review of Genomics and Human Genetics . 1 . 507–537 . 2000 . 11701639 . 10.1146/annurev.genom.1.1.507 . free .
  29. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families . Science . 261 . 5123 . 921–923 . August 1993 . 8346443 . 10.1126/science.8346443 . 1993Sci...261..921C .
  30. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD . Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease . Proceedings of the National Academy of Sciences of the United States of America . 90 . 5 . 1977–1981 . March 1993 . 8446617 . 46003 . 10.1073/pnas.90.5.1977 . free . 1993PNAS...90.1977S .
  31. Deary IJ, Whiteman MC, Pattie A, Starr JM, Hayward C, Wright AF, Carothers A, Whalley LJ . Cognitive change and the APOE epsilon 4 allele . Nature . 418 . 6901 . 932 . August 2002 . 12198535 . 10.1038/418932a . free . 4418270 . 1842/702 .
  32. Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC . Impact of APOE in mild cognitive impairment . Neurology . 63 . 10 . 1898–1901 . November 2004 . 15557508 . 10.1212/01.wnl.0000144279.21502.b7 . 21131734 .
  33. Saeed U, Desmarais P, Masellis M . The APOE ε4 variant and hippocampal atrophy in Alzheimer's disease and Lewy body dementia: a systematic review of magnetic resonance imaging studies and therapeutic relevance . Expert Review of Neurotherapeutics . 21 . 8 . 851–870 . August 2021 . 34311631 . 10.1080/14737175.2021.1956904 . 236451232 .
  34. Burt TD, Agan BK, Marconi VC, He W, Kulkarni H, Mold JE, Cavrois M, Huang Y, Mahley RW, Dolan MJ, McCune JM, Ahuja SK . Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression . Proceedings of the National Academy of Sciences of the United States of America . 105 . 25 . 8718–8723 . June 2008 . 18562290 . 2438419 . 10.1073/pnas.0803526105 . free .
  35. Chapman J, Vinokurov S, Achiron A, Karussis DM, Mitosek-Szewczyk K, Birnbaum M, Michaelson DM, Korczyn AD . APOE genotype is a major predictor of long-term progression of disability in MS . Neurology . 56 . 3 . 312–316 . February 2001 . 11171894 . 10.1212/wnl.56.3.312 . 40761206 .
  36. Schmidt S, Barcellos LF, DeSombre K, Rimmler JB, Lincoln RR, Bucher P, Saunders AM, Lai E, Martin ER, Vance JM, Oksenberg JR, Hauser SL, Pericak-Vance MA, Haines JL . Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis . American Journal of Human Genetics . 70 . 3 . 708–717 . March 2002 . 11836653 . 384947 . 10.1086/339269 .
  37. Friedman G, Froom P, Sazbon L, Grinblatt I, Shochina M, Tsenter J, Babaey S, Yehuda B, Groswasser Z . Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury . Neurology . 52 . 2 . 244–248 . January 1999 . 9932938 . 10.1212/wnl.52.2.244 . 131908791 .
  38. McCarron MO, Delong D, Alberts MJ . APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis . Neurology . 53 . 6 . 1308–1311 . October 1999 . 10522889 . 10.1212/wnl.53.6.1308 . 23443430 .
  39. Kadotani H, Kadotani T, Young T, Peppard PE, Finn L, Colrain IM, Murphy GM, Mignot E . Association between apolipoprotein E epsilon4 and sleep-disordered breathing in adults . JAMA . 285 . 22 . 2888–2890 . June 2001 . 11401610 . 10.1001/jama.285.22.2888 .
  40. Gottlieb DJ, DeStefano AL, Foley DJ, Mignot E, Redline S, Givelber RJ, Young T . APOE epsilon4 is associated with obstructive sleep apnea/hypopnea: the Sleep Heart Health Study . Neurology . 63 . 4 . 664–668 . August 2004 . 15326239 . 10.1212/01.wnl.0000134671.99649.32 . 12280483 .
  41. Jacobs EG, Kroenke C, Lin J, Epel ES, Kenna HA, Blackburn EH, Rasgon NL . Accelerated cell aging in female APOE-ε4 carriers: implications for hormone therapy use . PLOS ONE . 8 . 2 . e54713 . February 2013 . 23418430 . 3572118 . 10.1371/journal.pone.0054713 . free . 2013PLoSO...854713J .
  42. Wikgren M, Karlsson T, Nilbrink T, Nordfjäll K, Hultdin J, Sleegers K, Van Broeckhoven C, Nyberg L, Roos G, Nilsson LG, Adolfsson R, Norrback KF . APOE ε4 is associated with longer telomeres, and longer telomeres among ε4 carriers predicts worse episodic memory . Neurobiology of Aging . 33 . 2 . 335–344 . February 2012 . 20395015 . 10.1016/j.neurobiolaging.2010.03.004 . 27820056 .
  43. Honig LS, Schupf N, Lee JH, Tang MX, Mayeux R . Shorter telomeres are associated with mortality in those with APOE epsilon4 and dementia . Annals of Neurology . 60 . 2 . 181–187 . August 2006 . 16807921 . 10.1002/ana.20894 . 73120632 .
  44. Dhillon VS, Deo P, Chua A, Thomas P, Fenech M . Shorter Telomere Length in Carriers of APOE-ε4 and High Plasma Concentration of Glucose, Glyoxal and Other Advanced Glycation End Products (AGEs) . The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences . 75 . 10 . 1894–1898 . September 2020 . 31541246 . 10.1093/gerona/glz203 .
  45. Raber J . AR, apoE, and cognitive function . Hormones and Behavior . 53 . 5 . 706–715 . May 2008 . 18395206 . 2409114 . 10.1016/j.yhbeh.2008.02.012 .
  46. Kuo CL, Pilling LC, Atkins JL, Masoli JA, Delgado J, Kuchel GA, Melzer D . APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort . The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences . 75 . 11 . 2231–2232 . October 2020 . 32451547 . 7314139 . 10.1093/gerona/glaa131 . free .
  47. Huebbe P, Nebel A, Siegert S, Moehring J, Boesch-Saadatmandi C, Most E, Pallauf J, Egert S, Müller MJ, Schreiber S, Nöthlings U, Rimbach G . APOE ε4 is associated with higher vitamin D levels in targeted replacement mice and humans . FASEB Journal . 25 . 9 . 3262–3270 . September 2011 . 21659554 . 10.1096/fj.11-180935 . free . 22483645 .
  48. Jasienska G, Ellison PT, Galbarczyk A, Jasienski M, Kalemba-Drozdz M, Kapiszewska M, Nenko I, Thune I, Ziomkiewicz A . Apolipoprotein E (ApoE) polymorphism is related to differences in potential fertility in women: a case of antagonistic pleiotropy? . Proceedings. Biological Sciences . 282 . 1803 . 20142395 . March 2015 . 25673673 . 4345437 . 10.1098/rspb.2014.2395 .
  49. Oriá RB, Patrick PD, Oriá MO, Lorntz B, Thompson MR, Azevedo OG, Lobo RN, Pinkerton RF, Guerrant RL, Lima AA . ApoE polymorphisms and diarrheal outcomes in Brazilian shanty town children . Brazilian Journal of Medical and Biological Research = Revista Brasileira de Pesquisas Medicas e Biologicas . 43 . 3 . 249–256 . March 2010 . 20401432 . 3057459 . 10.1590/s0100-879x2010007500003 .
  50. Becher JC, Keeling JW, Bell J, Wyatt B, McIntosh N . Apolipoprotein E e4 and its prevalence in early childhood death due to sudden infant death syndrome or to recognised causes . Early Human Development . 84 . 8 . 549–554 . August 2008 . 18280677 . 10.1016/j.earlhumdev.2008.01.002 .
  51. Sundermann EE, Wang C, Katz M, et al. Cholesteryl ester transfer protein genotype modifies the effect of apolipoprotein ε4 on memory decline in older adults. Neurobiol Aging. 2016;41:200.e7-200.e12. doi:10.1016/j.neurobiolaging.2016.02.006
  52. Mondadori CR, de Quervain DJ, Buchmann A, Mustovic H, Wollmer MA, Schmidt CF, Boesiger P, Hock C, Nitsch RM, Papassotiropoulos A, Henke K . Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers . Cerebral Cortex . 17 . 8 . 1934–1947 . August 2007 . 17077159 . 10.1093/cercor/bhl103 . free . 20.500.11850/5720 . free .
  53. Huynh RA, Mohan C . Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid . Frontiers in Neurology . 8 . 102 . 2017 . 28373857 . 5357660 . 10.3389/fneur.2017.00102 . free .
  54. Miyashita A, Kikuchi M, Hara N, Ikeuchi T . Genetics of Alzheimer's disease: an East Asian perspective . Journal of Human Genetics . 68 . 3 . 115–124 . March 2023 . 35641666 . 9968656 . 10.1038/s10038-022-01050-z .
  55. Book: Baars HF, van der Smagt JJ, Doevandans PA . Clinical Cardiogenetics . 2011 . Springer . London . 978-1849964715 .
  56. Zhang Z, Mu J, Li J, Li W, Song J . Aberrant apolipoprotein E expression and cognitive dysfunction in patients with poststroke depression . Genetic Testing and Molecular Biomarkers . 17 . 1 . 47–51 . January 2013 . 23171142 . 3525887 . 10.1089/gtmb.2012.0253 .
  57. Rogers JT, Weeber EJ . Reelin and apoE actions on signal transduction, synaptic function and memory formation . Neuron Glia Biology . 4 . 3 . 259–270 . August 2008 . 19674510 . 10.1017/S1740925X09990184 .
  58. Sacks FM . The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia . Current Opinion in Lipidology . 26 . 1 . 56–63 . February 2015 . 25551803 . 4371603 . 10.1097/MOL.0000000000000146 .
  59. Jiang L, Zhong J, Dou X, Cheng C, Huang Z, Sun X . Effects of ApoE on intracellular calcium levels and apoptosis of neurons after mechanical injury . Neuroscience . 301 . 375–383 . August 2015 . 26073697 . 10.1016/j.neuroscience.2015.06.005 . 42716198 .
  60. van den Elzen P, Garg S, León L, Brigl M, Leadbetter EA, Gumperz JE, Dascher CC, Cheng TY, Sacks FM, Illarionov PA, Besra GS, Kent SC, Moody DB, Brenner MB . Apolipoprotein-mediated pathways of lipid antigen presentation . Nature . 437 . 7060 . 906–910 . October 2005 . 16208376 . 10.1038/nature04001 . 3109596 . 2005Natur.437..906E .
  61. Zhang HL, Wu J, Zhu J . The role of apolipoprotein E in Guillain-Barré syndrome and experimental autoimmune neuritis . Journal of Biomedicine & Biotechnology . 2010 . 357412 . 2010 . 20182542 . 2825561 . 10.1155/2010/357412 . free .
  62. Braesch-Andersen S, Paulie S, Smedman C, Mia S, Kumagai-Braesch M . ApoE production in human monocytes and its regulation by inflammatory cytokines . PLOS ONE . 8 . 11 . e79908 . 2013 . 24244577 . 3828220 . 10.1371/journal.pone.0079908 . free . 2013PLoSO...879908B .
  63. Sadigh-Eteghad S, Talebi M, Farhoudi M . Association of apolipoprotein E epsilon 4 allele with sporadic late onset Alzheimer's disease. A meta-analysis . Neurosciences . 17 . 4 . 321–326 . October 2012 . 23022896 .
  64. Sepehrnia B, Kamboh MI, Adams-Campbell LL, Bunker CH, Nwankwo M, Majumder PP, Ferrell RE . Genetic studies of human apolipoproteins. X. The effect of the apolipoprotein E polymorphism on quantitative levels of lipoproteins in Nigerian blacks . American Journal of Human Genetics . 45 . 4 . 586–591 . October 1989 . 2491016 . 1683508 .
  65. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A . Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease . Neuroepidemiology . 17 . 1 . 14–20 . 1998-01-01 . 9549720 . 10.1159/000026149 . 71543885 .
  66. Petanceska SS, DeRosa S, Sharma A, Diaz N, Duff K, Tint SG, Refolo LM, Pappolla M . Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol . Journal of Molecular Neuroscience . 20 . 3 . 395–406 . 2003-01-01 . 14501024 . 10.1385/JMN:20:3:395 . 35969696 .
  67. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H . Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease . Annals of Internal Medicine . 137 . 3 . 149–155 . August 2002 . 12160362 . 10.7326/0003-4819-137-3-200208060-00006 . 23780605 .
  68. Wisniewski T, Frangione B . Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid . Neuroscience Letters . 135 . 2 . 235–238 . February 1992 . 1625800 . 10.1016/0304-3940(92)90444-C . 8839627 . free .
  69. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE . ApoE promotes the proteolytic degradation of Abeta . Neuron . 58 . 5 . 681–693 . June 2008 . 18549781 . 2493297 . 10.1016/j.neuron.2008.04.010 .
  70. Thambisetty M, Howard R, Glymour MM, Schneider LS . Alzheimer's drugs: Does reducing amyloid work? . Science . 374 . 6567 . 544–545 . October 2021 . 34709898 . 10.1126/science.abl8366 . 240152869 . 2021Sci...374..544T .
  71. Kovács KA . Relevance of a Novel Circuit-Level Model of Episodic Memories to Alzheimer's Disease . International Journal of Molecular Sciences . 23 . 1 . 462 . December 2021 . 35008886 . 8745479 . 10.3390/ijms23010462 . free .
  72. Hauser PS, Ryan RO . Impact of apolipoprotein E on Alzheimer's disease . Current Alzheimer Research . 10 . 8 . 809–817 . October 2013 . 23919769 . 3995977 . 10.2174/15672050113109990156 .
  73. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Rimmler JB, Locke PA, Conneally PM, Schmader KE . Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease . Nature Genetics . 7 . 2 . 180–184 . June 1994 . 7920638 . 10.1038/ng0694-180 . 11137478 .
  74. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium . JAMA . 278 . 16 . 1349–1356 . 1997 . 9343467 . 10.1001/jama.1997.03550160069041 .
  75. Damoiseaux JS, Seeley WW, Zhou J, Shirer WR, Coppola G, Karydas A, Rosen HJ, Miller BL, Kramer JH, Greicius MD . Gender modulates the APOE ε4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels . The Journal of Neuroscience . 32 . 24 . 8254–8262 . June 2012 . 22699906 . 3394933 . 10.1523/JNEUROSCI.0305-12.2012 .
  76. Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Trojanowski JQ, Weintraub D, Chen-Plotkin AS, Irwin DJ, Rick J, Schellenberg GD, Watson GS, Kukull W, Nelson PT, Jicha GA, Neltner JH, Galasko D, Masliah E, Quinn JF, Chung KA, Yearout D, Mata IF, Wan JY, Edwards KL, Montine TJ, Zabetian CP . APOE ε4 increases risk for dementia in pure synucleinopathies . JAMA Neurology . 70 . 2 . 223–228 . February 2013 . 23407718 . 3580799 . 10.1001/jamaneurol.2013.600 .
  77. Saeed U, Desmarais P, Masellis M . The APOE ε4 variant and hippocampal atrophy in Alzheimer's disease and Lewy body dementia: a systematic review of magnetic resonance imaging studies and therapeutic relevance . Expert Review of Neurotherapeutics . 21 . 8 . 851–870 . August 2021 . 34311631 . 10.1080/14737175.2021.1956904 . 236451232 .
  78. McNeill E, Channon KM, Greaves DR . Inflammatory cell recruitment in cardiovascular disease: murine models and potential clinical applications . Clinical Science . 118 . 11 . 641–655 . March 2010 . 20210786 . 10.1042/CS20090488 .
  79. Kassa FA, Van Den Ham K, Rainone A, Fournier S, Boilard E, Olivier M . Absence of apolipoprotein E protects mice from cerebral malaria . Scientific Reports . 6 . 33615 . September 2016 . 27647324 . 5028887 . 10.1038/srep33615 . 2016NatSR...633615K .
  80. Wozniak MA, Riley EM, Itzhaki RF . Apolipoprotein E polymorphisms and risk of malaria . Journal of Medical Genetics . 41 . 3 . 145–146 . March 2004 . 14985370 . 1735716 . 10.1136/jmg.2003.014613 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Apolipoprotein E".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.